Prostaglandin-endoperoxide synthase (peroxidase site) (PTGS) (PTGS (peroxidase))

The peroxidase-linked site of prostaglandin-endoperoxide synthase (PTGS), often associated with the central action of acetaminophen, is a distinct catalytic domain within the COX enzyme complex. While the cyclooxygenase site is responsible for converting arachidonic acid to prostaglandin G2 (PGG2), the peroxidase site reduces PGG2 to prostaglandin H2 (PGH2), the common precursor for all prostanoids (Aronoff et al., 2006). This site serves as the primary target for non-acidic analgesics like acetaminophen, which act as reducing agents to interrupt the enzyme's catalytic cycle (Graham & Scott, 2005). The efficacy of drugs targeting this site is highly dependent on the 'peroxide tone' of the local environment; they are most potent in the central nervous system where hydroperoxide concentrations are low, but their activity is neutralized in peripheral tissues during intense inflammation (Boutaud et al., 2002). Historically, a splice variant of COX-1 termed COX-3 was proposed as the specific central target for these drugs, though its functional significance in humans remains a topic of debate compared to the broader inhibition of the peroxidase activity of standard COX-1 and COX-2 (Chandrasekharan et al., 2002). Understanding the unique biochemistry of this site is crucial for developing analgesics that provide effective pain and fever relief while avoiding the gastrointestinal and cardiovascular side effects typical of traditional NSAIDs.

Other names

Cyclooxygenase peroxidase siteCOX peroxidase domainCyclooxygenase-3COX-3Central cyclooxygenase site

The mechanism involves the reduction of the ferryl-protoporphyrin IX radical ($Fe^{4+}=O$) within the peroxidase active site to its resting ferric state ($Fe^{3+}$). This prevents the abstraction of a hydrogen atom from arachidonic acid at the cyclooxygenase site, which is required to initiate prostaglandin synthesis (Aronoff et al., 2006; Lucas et al., 2005). This inhibitory effect is competitive with hydroperoxides, explaining why the drug is more effective in the central nervous system where peroxide levels are low (Graham & Scott, 2005).